We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis is joining the emerging pay-for-performance trend, inking a deal with health insurers Aetna and Cigna for its new heart failure drug Enestro. Read More
Federal efforts to protect the drug supply chain continue to bear fruit, with the FDA’s Office of Criminal Investigations announcing criminal charges for another counterfeit operation. Read More
After serving as Gilead Sciences’ CEO for 20 years, John C. Martin has announced that he is stepping down and will assume the role of executive chairman of the company. Read More
Democrats and Republicans of the House Oversight Committee took executives of Valeant Pharmaceuticals and Turing Pharmaceuticals to task on Thursday over what members called a strategy of buying old drugs with no generic competition and “jacking up” the prices for profits. Read More
Federal efforts to protect the drug supply chain continue to bear fruit, with the FDA’s Office of Criminal Investigations announcing criminal charges for another counterfeit operation. Read More
Patent cases involving payments by brand drugmakers to delay generic competition have dropped 27 percent following a 2013 challenge to the practice, according to the Federal Trade Commission. Read More